Core Insights - California is experiencing a pharmaceutical renaissance, driven by significant investments from major biopharma companies like Amgen and Gilead, focusing on science, supply chains, and innovative therapies [1][4]. Group 1: Amgen's Investment - Amgen has invested $600 million to establish a state-of-the-art science and innovation center at its headquarters in Thousand Oaks, CA, aimed at enhancing collaboration among scientists, engineers, and researchers [2]. - This investment is part of Amgen's broader strategy, which has seen the company allocate over $40 billion into domestic manufacturing and R&D since the 2017 Tax Cuts and Jobs Act, including more than $5 billion in direct capital expenditures [3]. Group 2: Gilead's Development Initiatives - Gilead Sciences has initiated the construction of a new Technical Development Hub to accelerate biopharma innovation in the U.S., highlighting the importance of specialized infrastructure in the industry [4]. Group 3: Supply Chain Modernization - The investments from these companies also contribute to the modernization of supply chains, which are now viewed as critical systems requiring transparency, flexibility, and resilience [5]. - Advanced cold chain management practices are being developed, utilizing predictive analytics to monitor not only temperature but also equipment functionality, which is essential for therapeutic delivery [6]. Group 4: California's Biopharma Ecosystem - The current investments reflect California's reassertion as a national life sciences engine, fostering partnerships between academia and startups through its R&D hubs [8].

Company Participation - Jazz Pharmaceuticals will participate in the 2025 Wells Fargo Healthcare Conference with a fireside chat scheduled for September 3, 2025, at 6:30 a.m. PDT / 9:30 p.m. EDT / 2:30 p.m. IST [1] Webcast Information - An audio webcast of the fireside chat will be available on the Investors section of the Jazz Pharmaceuticals website, with a replay archived for 30 days [2] Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, including sleep disorders, epilepsy, and cancer treatments [3] - The company is headquartered in Dublin, Ireland, and has a diverse portfolio of marketed medicines and a robust pipeline in oncology and neuroscience [3]